In a trial, Gossamer Bio's PAH treatment candidate seralutinib reduced the resistance blood faces moving into the lungs over ...

Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients ...

Gossamer Bio Inc. has released new data showing its inhaled kinase inhibitor, seralutinib, has long-lasting effects on ...

Taking place on February 14-16, 2025, in Washington, the American College of Cardiology (ACC) Advancing the Cardiovascular Care of the Oncology Patient conference is an interdisciplinary and ...

United Therapeutics (UTHR) announced full enrollment of the TETON 1 study evaluating the use of Tyvaso or treprostinil, inhalation solution or ...

SAN DIEGO - Gossamer Bio, Inc. (NASDAQ:GOSS), a biopharmaceutical company in the clinical stage with a market capitalization of $225 million, has shared new research findings on its drug candidate ...

Merck is ending a Phase 3 trial of Winrevair early so all PAH patients in HYPERION can start active treatment with the drug ...

The HYPERION study was evaluating Winrevair in recently diagnosed adults with pulmonary arterial hypertension.

Merck said the Phase 3 "Hyperion" study, which was evaluating Winrevair versus placebo in recently diagnosed adults with PAH at intermediate or high risk of disease progression, had lost clinical ...

Receiving a diagnosis for any disease/condition is not an easy experience. One organization hopes to make patients newly ...